Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database
Open Access
- 17 June 2024
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 89 (2) , 106202
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (JP20K16035)
- Japan Science and Technology Agency
- Japan Science and Technology Agency Strategic Basic Research Programs CREST (JPMJCR22N1)
This publication has 22 references indexed in Scilit:
- Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving LansoprazoleJAMA Network Open, 2023
- Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 GuidelinesCurrent Oncology Reports, 2023
- Proton pump inhibitor use: systematic review of global trends and practicesEuropean Journal of Clinical Pharmacology, 2023
- Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data CenterDrugs - Real World Outcomes, 2022
- Data resource profile: JMDC claims databases sourced from Medical InstitutionsJournal of General and Family Medicine, 2020
- Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes RiskJACC, 2017
- Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT ProlongationJACC, 2016
- Ventricular arrhythmias and sudden cardiac deathThe Lancet, 2012
- Failing the Acid TestArchives of internal medicine (1960), 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007